Literature DB >> 17280823

Chitosan microspheres enhance the immunogenicity of an Ag85B-based fusion protein containing multiple T-cell epitopes of Mycobacterium tuberculosis.

Bing dong Zhu1, Ya qing Qie, Jiu ling Wang, Ying Zhang, Qing zhong Wang, Ying Xu, Hong hai Wang.   

Abstract

To develop novel delivery system for tuberculosis (TB) subunit vaccine, biodegradable chitosan microspheres were prepared and used to deliver a fusion protein, Ag85B-MPT64(190-198)-Mtb8.4 (AMM for short), made from three Mycobacterium tuberculosis genes. AMM-loaded microspheres were first characterized for their morphology, size, zeta potential, loading efficiency, and in vitro release of AMM. C57BL/6 mice were immunized at weeks 1, 3 and 5 subcutaneously with AMM formulated in chitosan microspheres, in incomplete Freund's adjuvant (IFA), or in phosphate-buffered saline (PBS), respectively. Three weeks after the last immunization, humoral and cell-mediated immune responses were examined. It was shown that the microspheres bound AMM quite efficiently (loading efficiency: >99%). AMM-loaded chitosan microspheres were observed as aggregated shapes with the average particle size of 5.78+/-0.65 microm and zeta potential of 32.77+/-1.51 mV. In vitro release studies revealed that only small amount of antigen was released in 16 days. Following subcutaneous administration, splenocytes immunized with AMM in chitosan microspheres produced higher levels of IFN-gamma compared to administration of AMM in PBS upon stimulation with Ag85B and synthetic peptide MPT64(190-198). The levels of Ag85B-specific IgG (H+L), IgG1 and IgG2a in sera of mice immunized with AMM in chitosan microspheres were also higher than those with AMM in PBS. These results indicate that chitosan microspheres when used as a carrier for fusion protein AMM could elicit strong humoral and cell-mediated immune responses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17280823     DOI: 10.1016/j.ejpb.2006.11.028

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  10 in total

Review 1.  Recent advancement of chitosan-based nanoparticles for oral controlled delivery of insulin and other therapeutic agents.

Authors:  Anumita Chaudhury; Surajit Das
Journal:  AAPS PharmSciTech       Date:  2010-12-11       Impact factor: 3.246

2.  Th immune response induced by H pylori vaccine with chitosan as adjuvant and its relation to immune protection.

Authors:  Yong Xie; Nan-Jin Zhou; Yan-Feng Gong; Xiao-Jiang Zhou; Jiang Chen; Si-Juan Hu; Nong-Hua Lu; Xiao-Hua Hou
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

3.  Vaccine-like controlled-release delivery of an immunomodulating peptide to treat experimental autoimmune encephalomyelitis.

Authors:  Barlas Büyüktimkin; Qun Wang; Paul Kiptoo; John M Stewart; Cory Berkland; Teruna J Siahaan
Journal:  Mol Pharm       Date:  2012-03-13       Impact factor: 4.939

4.  Preparation and evaluation of biopolymeric nanoparticles as drug delivery system in effective treatment of rheumatoid arthritis.

Authors:  Vijay Kumar; Ankita Leekha; Aakriti Tyagi; Ankur Kaul; Anil Kumar Mishra; Anita Kamra Verma
Journal:  Pharm Res       Date:  2017-01-17       Impact factor: 4.200

Review 5.  Brucellosis: the case for live, attenuated vaccines.

Authors:  Thomas A Ficht; Melissa M Kahl-McDonagh; Angela M Arenas-Gamboa; Allison C Rice-Ficht
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

6.  Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice.

Authors:  Mohammad Ali Danesh-Bahreini; Javad Shokri; Afshin Samiei; Eskandar Kamali-Sarvestani; Mohammad Barzegar-Jalali; Soliman Mohammadi-Samani
Journal:  Int J Nanomedicine       Date:  2011-04-20

7.  Effects of the polysaccharide nucleic acid fraction of bacillus Calmette-Guérin on the production of interleukin-2 and interleukin-10 in the peripheral blood lymphocytes of patients with chronic idiopathic urticaria.

Authors:  Na Li; Na Cao; Yan-Dong Niu; Xiu-Hui Bai; Jie Lu; Yu Sun; Min Yu; Li-Xin Sun; Xin-Suo Duan
Journal:  Biomed Rep       Date:  2013-07-04

8.  Chitosan nanoparticles act as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice.

Authors:  Zheng-Shun Wen; Ying-Lei Xu; Xiao-Ting Zou; Zi-Rong Xu
Journal:  Mar Drugs       Date:  2011-06-14       Impact factor: 6.085

9.  Nanoparticle or conventional adjuvants: which one improves immune response against Brucellosis?

Authors:  Soheil Yousefi; Tooba Abbassi-Daloii; Mojtaba Tahmoorespur; Mohammad Hadi Sekhavati
Journal:  Iran J Basic Med Sci       Date:  2019-04       Impact factor: 2.699

Review 10.  Potential of polymeric particles as future vaccine delivery systems/adjuvants for parenteral and non-parenteral immunization against tuberculosis: A systematic review.

Authors:  Farzad Khademi; Mohammad Derakhshan; Arshid Yousefi-Avarvand; Mohsen Tafaghodi
Journal:  Iran J Basic Med Sci       Date:  2018-02       Impact factor: 2.699

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.